AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
Nov 16, 2021
29864_dirs_2021-11-16_065c04ac-cbbc-4a76-ad92-dd6ab0b39115.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-11-15
Reporting Person: ALTSHULER DAVID (EVP, Global Research and CSO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-11-15 | Common Stock | S | 14 | $186.80 | Disposed | 33609 | Direct |
| 2021-11-15 | Common Stock | S | 20 | $187.51 | Disposed | 33589 | Direct |
Footnotes
F1: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $186.80 (range $186.22 to $187.19).
F3: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $187.51 (range $187.26 to $187.79).